1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 0,023 | 0,027 | 13:04 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 30.01. | Genflow Biosciences PLC Announces Holding(s) in Company | 221 | ACCESS Newswire | LONDON, UK / ACCESS Newswire / January 30, 2026 / TR-1: Standard form for notification of major holdings1. Issuer DetailsISINGB00BP2C3V08Issuer NameGENFLOW BIOSCIENCES PLCUK or Non-UK IssuerUK2. Reason... ► Artikel lesen | |
| 28.01. | Genflow Biosciences PLC Announces Administrative Approval of Grant & 2026 Priorities | 125 | ACCESS Newswire | LONDON, UK / ACCESS Newswire / January 28, 2026 / THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE MARKET ABUSE REGULATION... ► Artikel lesen | |
| GENFLOW BIOSCIENCES Aktie jetzt für 0€ handeln | |||||
| 28.01. | Genflow Biosciences - Administrative Approval of Grant & 2026 Priorities | - | RNS | ||
| 19.01. | EXECUTIVE CHANGES: Genflow Biosciences names Berdugo as new chair | 1 | Alliance News | ||
| 19.01. | Genflow Biosciences PLC Announces Directorate Change | 230 | ACCESS Newswire | THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE MARKET ABUSE REGULATION (EU) NO. 596/2014 AS IT FORMS PART OF UK... ► Artikel lesen | |
| 19.01. | Genflow Biosciences appoints new chairman to lead expansion | 2 | Investing.com | ||
| 19.01. | Genflow Biosciences - Directorate change | 2 | RNS | ||
| 08.01. | TRADING UPDATES: Genflow Biosciences lays out hopes for 2026 | 1 | Alliance News | ||
| 08.01. | Genflow: Gentherapie-Studie bei Hunden ohne unerwünschte Ereignisse | 1 | Investing.com Deutsch | ||
| 08.01. | Genflow reports no adverse events in dog aging gene therapy trial | 1 | Investing.com | ||
| 08.01. | Genflow Biosciences - Review of 2025 | - | RNS | ||
| 16.12.25 | Genflow Biosciences PLC: Genflow Completes Dosing Phase of Canine Gene Therapy Trial | 288 | ACCESS Newswire | THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE MARKET ABUSE REGULATION (EU) NO. 596/2014 AS IT FORMS PART OF UK... ► Artikel lesen | |
| 16.12.25 | Genflow Biosciences - Completion of Dosing Phase of Canine Gene Therapy | 1 | RNS | ||
| 11.12.25 | Genflow Biosciences to attend J.P. Morgan Healthcare Conference | 2 | Investing.com | ||
| 11.12.25 | Genflow Biosciences nimmt an J.P. Morgan Healthcare Conference teil | 4 | Investing.com Deutsch | ||
| 11.12.25 | Genflow Biosciences PLC: Genflow to Attend Healthcare Conference | 249 | ACCESS Newswire | Genflow to Attend the 44th Annual J.P. Morgan Healthcare Conference LONDON, UK / ACCESS Newswire / December 11, 2025 / Genflow Biosciences Plc (LSE:GENF)(OTCQB:GENFF) ("Genflow" or "the Company"), a... ► Artikel lesen | |
| 11.12.25 | Genflow Biosciences - Genflow to Attend Healthcare Conference | 2 | RNS | ||
| 31.10.25 | Genflow Biosciences PLC Announces Total Voting Rights | 260 | ACCESS Newswire | LONDON, UK / ACCESS Newswire / October 31, 2025 / Genflow Biosciences Plc (LSE:GENF)(OTCQB:GENFF) ("Genflow" or "the Company"), an emerging leader in the field of longevity research, focused on developing... ► Artikel lesen | |
| 31.10.25 | Genflow Biosciences - Total Voting Rights | 2 | RNS | ||
| 24.10.25 | Genflow Biosciences PLC Announces Holding(s) in Company | 244 | ACCESS Newswire | LONDON, UK / ACCESS Newswire / October 24, 2025 / TR-1: Standard form for notification of major holdings1. Issuer DetailsISINGB00BP2C3V08Issuer NameGENFLOW BIOSCIENCES PLCUK or Non-UK IssuerUK2. Reason... ► Artikel lesen |
1 2 3 4 Weiter >>
67 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| CRISPR THERAPEUTICS | 41,200 | -0,48 % | Morningstar, Inc.: Morningstar Completes Acquisition of CRSP and Extends Relationship with Vanguard | The CRSP integration unites two trusted sources of market insight, reinforcing a shared commitment to transparency, quality, and investor-focused solutions and solidifying Morningstar's position... ► Artikel lesen | |
| PACIFIC BIOSCIENCES OF CALIFORNIA | 1,568 | +2,10 % | PacBio Completes Sale of Short-Read Sequencing Assets | MENLO PARK, Calif., Feb. 02, 2026 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, today announced the completion of the sale of... ► Artikel lesen | |
| DENALI THERAPEUTICS | 17,655 | -0,93 % | Denali, Royalty Pharma Ink $275Mln Royalty Financing Agreement | WASHINGTON (dpa-AFX) - Denali Therapeutics Inc. (DNLI) and Royalty Pharma plc (RPRX) on Thursday announced a $275 million synthetic royalty funding agreement tied to future net sales of Tividenofusp... ► Artikel lesen | |
| VOYAGER THERAPEUTICS | 3,126 | +0,51 % | Voyager Therapeutics, Inc.: Voyager Reports Third Quarter 2025 Financial and Operating Results |
- Momentum building around tau: expect VY7523 clinical data and VY1706 clinical entry in 2026 - - Sharpened focus on multi-modality pipeline with introduction of Voyager NeuroShuttle discovery... ► Artikel lesen | |
| BIOAGE LABS | 16,600 | -5,68 % | AKTIONÄR-Tipp BioAge Labs wird entdeckt: 272 Prozent Kurspotenzial! | Der Megatrend Longevity hat nun auch die Aktie von BioAge Labs erfasst. Ausgehend vom 52-Wochen-Tief bei 2,88 Dollar konnte sich der Titel auf aktuell 19,60 Dollar zuletzt vervielfachen. Und die Analysten... ► Artikel lesen | |
| LINEAGE CELL THERAPEUTICS | 1,430 | -0,69 % | Regenerative Medizin auf dem Vormarsch: Exosomen, Gen- und Zelltherapien als Wegbereiter neuer Heilansätze | ||
| BIOPHYTIS | 0,038 | 0,00 % | XFRA CAPITAL ADJUSTMENT INFORMATION - 09.12.2025 | Das Instrument 6XB3 FR001400OLP5 BIOPHYTIS NAM. EO -,10 EQUITY wird cum Kapitalmassnahme gehandelt am 09.12.2025 und ex Kapitalmassnahme am 10.12.2025 The instrument 6XB3 FR001400OLP5 BIOPHYTIS NAM.... ► Artikel lesen | |
| SERINA THERAPEUTICS | 2,080 | +4,52 % | Morning Market Movers: Serina Therapeutics, Digital Currency X, Virtuix, Inuvo See Big Swings | OTTAWA (dpa-AFX) - At 8:15 a.m. ET on Thursday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the opening... ► Artikel lesen | |
| LONGEVERON | 0,513 | +0,39 % | Longeveron Applauds Passage of the Mikaela Naylon Give Kids a Chance Act and Reauthorization of Rare Pediatric Disease Priority Review Voucher Program | ||
| PRAXIS PRECISION MEDICINES | 319,57 | +4,56 % | Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | ||
| QIAGEN | 43,170 | -0,70 % | Ionos, Kontron, Lanxess, Qiagen, Redcare Pharmacy, Siltronic, TeamViewer: Neue Aktien-Positionen der Short-Seller | Wer Aktien leerverkauft, also auf fallende Kurse spekuliert (Shortselling), unterliegt bestimmten Transparenzpflichten. Aktuelle Meldungen über Leerverkäufe geben Aufschluss darüber. Diese Vorgaben... ► Artikel lesen | |
| AVIDITY BIOSCIENCES | 72,90 | +0,11 % | Avidity Biosciences, Inc. - 8-K, Current Report | ||
| TARSUS PHARMACEUTICALS | 64,62 | +4,24 % | Tarsus Pharmaceuticals, Inc: Tarsus Reports Third Quarter 2025 Financial Results and Recent Business Achievements | Delivered quarterly XDEMVY® net sales of approximately $119 million, up approximately 147% year-over-year Weekly multi-patient prescribers grew approximately 30% in the third quarter underscoring... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 14,990 | +8,23 % | H.C. Wainwright reiterates Buy rating on Summit Therapeutics stock | ||
| ERASCA | 12,290 | +3,45 % | Erasca, Inc.: Erasca Announces Pricing of Upsized Public Offering of Common Stock | SAN DIEGO, Jan. 21, 2026 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for... ► Artikel lesen |
Das Unternehmen GENFLOW BIOSCIENCES PLC kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell -6,38 % bei einem Aktienkurs von 0,022 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu GENFLOW BIOSCIENCES PLC finden Sie auf Wallstreet Online.